Analyst Highlights ‘Rock Solid’ Data For Vera Therapeutics’ Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
Thursday, Vera Therapeutics Inc (NASDAQ:VERA) announced 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).
Data from the OLE show the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks in participants with IgAN.
Raymond James analysts Ryan Deschner and Steven Seedhouse upgraded Vera Therapeutics, noting that the data set exceeded their expectations.
The analysts write that the data confirms that atacicept is the most low-risk drug candidate for IgA nephropathy (IgAN).
The dataset establishes …
Full story available on Benzinga.com